NCT00026221View on ClinicalTrials.gov

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Recurrent MelanomaStage IV Skin Melanoma
Interventions
BIOLOGICAL

Recombinant Interferon Alfa

Given SC

BIOLOGICAL

Bevacizumab

Given IV

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center, Columbus

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00026221 - Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter